# Osanni Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/osanni-bio

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.osanni.bio
- Total disclosed funding: $190M
- Latest round: Series B (Jun 23, 2026)
- Investors on record: 4

## About

Osanni Bio, Inc. is a US-based biotechnology firm specializing in the development of innovative therapeutic medicines, particularly within ophthalmology and cardiology, aimed at addressing critical unmet medical needs. Founded in 2022 and headquartered in San Francisco, US, Osanni Bio, Inc. focuses on transformative therapies for various diseases. Michael Ackermann, Ph.D. is the founder and Chief Executive Officer (CEO) of Osanni Bio, a development-stage therapeutics platform focused on discovering and developing innovative medicines. The company has successfully raised a total of USD 190.00 mn through its Series B funding round, led by Patient Square Capital, and has partnered with other investors like Horowitz Group, Invus Financial Advisors, and Retinal Degeneration Fund. Osanni Bio specializes in the discovery and development of transformative therapeutic medicines, with a strong focus on ophthalmology and cardiology. The company's core offerings stem from an innovative approach that integrates biodesign principles, advanced technology, and capital efficiency to address significant unmet medical needs. Osanni's products are designed to provide novel solutions for various diseases, particularly in areas where traditional therapies have proven inadequate. The company's pipeline consists of multiple programs that advance through a systematic process of de-risking, leading to a proof-of-concept for new drug concepts before they are transitioned to its ecosystem of affiliate companies, termed "Avians." Osanni Bio strategically targets markets in North America and Europe, aiming to improve patient outcomes for both healthcare providers and patients dealing with chronic conditions.Osanni Bio's revenue model is primarily based on the successful advancement of its therapeutic programs and subsequent commercialization through its affiliate companies. The company engages in strategic partnerships to enhance its product offerings, which could include collaborations with healthcare providers and pharmaceutical distributors. Transactions within this framework may involve direct sales of developed therapeutics to healthcare facilities or agreements that facilitate the distribution of their products through established medical supply chains. The structure of these transactions generally aligns with B2B relationships, where Osanni Bio works closely with industry partners to ensure that its innovative medicines reach the end users efficiently. The financial dynamics revolve around the successful launch of its pipeline programs, leading to potential revenue generation from flagship products as they gain market acceptance.Osanni Bio is focused on advancing the development of its therapeutic programs, with ongoing designs for new products targeted for launch in the coming years. The company has plans to expand into both North American and European markets to increase patient access to its innovative therapies. Recent funding, raised during the Series B round, will be utilized to support these growth initiatives, enabling Osanni Bio to enhance its product pipeline and accelerate its market entry strategies.

## Funding rounds

- Series B, Jun 23, 2026, $190M — Invus Financial Advisors, Horowitz Group, Patient Square Capital, Retinal Degeneration Fund

## Investors

- Invus Financial Advisors (https://capitalatlas.ai/funds/invus-financial-advisors) — Series B
- Horowitz Group — Series B
- Patient Square Capital (https://capitalatlas.ai/funds/patient-square-capital) — Series B
- Retinal Degeneration Fund (https://capitalatlas.ai/funds/retinal-degeneration-fund) — Series B